Kosan drug fails prostate cancer trial
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Kosan's epothilone compound KOS-862 (epothilone D) did not meet the primary endpoint of response in a Phase II trial in hormone refractory prostate cancer, the firm says Oct. 18. The company is discontinuing the trial and focusing on an ongoing Phase II study of KOS-862 as monotherapy in metastatic breast cancer. KOS-862 inhibits cancer cells by the same mechanism as taxanes, Kosan explains. A follow-on compound to KOS-862, KOS-1584, is in Phase I. Kosan is developing its epothilones under a 2002 agreement with Roche...
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.